Deborah Mash
Professor of Neurology at the University of Miami Miller School of Medicine
Data updated
Research Footprint
Deborah Mash appears in 6 tracked papers (1999–2023), most studied alongside Ibogaine and Ayahuasca, across Substance Use Disorders (SUD), Medicinal Chemistry & Drug Development and Veterans.
Most-cited paper: Pharmacokinetics of Hoasca alkaloids in healthy humans (307 citations).
Frequent co-authors: Dalibor Sames, Ignacio Carrera and Charles Grob.
Background & Research
Deborah C. Mash is an American neuroscientist and physician-scientist whose work has focused on addiction, neuropharmacology, and the brain effects of psychoactive compounds. She is best known for her long-running research on ibogaine and noribogaine, including preclinical studies, human detoxification observations, and pharmacokinetic work. She has held a professorship in neurology at the University of Miami Miller School of Medicine and has been associated with ibogaine research efforts there.
Key Impact
A pioneering ibogaine and addiction researcher whose work helped establish the scientific and clinical literature on ibogaine, noribogaine, and psychedelic-assisted treatment for substance use disorders.
Collaboration Network
3 collaborators· click a node to visit their profile
Full network →Affiliations
Institutions, companies, and organisations Deborah Mash is associated with.
University of Miami Miller School of Medicine
The University of Miami Leonard M. Miller School of Medicine is the medical school of the University of Miami in Miami, Florida. It is a research-intensive institution that provides medical education, conducts biomedical research, and delivers clinical care as part of the University of Miami Health system.
View stakeholder →DemeRx
Private BiotechDemeRx is a clinical-stage biotech developing noribogaine (DMX-1001), a non-psychedelic active metabolite of ibogaine, as a treatment for alcohol use disorder. DMX-1001 promotes neuroplasticity to repair neural circuits damaged by chronic alcohol use. Phase 1b completed with favorable safety; Phase 2 AUD trial planned for 2026, supported by a $1.7M NIH SBIR grant.
View stakeholder →